Amazon has shut down a 4-year-old secret program working on a fertility monitoring device and accompanying smartphone app, CNBC reported.

The project, known under the code name “Encore,” grew out of Amazon’s 2020 purchase of a startup called bluDiagnostics, which was developing a device that measured levels of estradiol and progesterone — two of the hormones responsible for fertility in women – from saliva samples.

Amazon planned to launch the product this year, but the team of about 100 people encountered technical challenges, according to the report. Encore was part of the Amazon group Great challenge initiative, a secret laboratory known for undertaking daring or ambitious projects such as cancer research.

Andy Jassy, ​​the company’s CEO, has been on a cost-cutting journey since 2022. In addition to cutting 27,000 jobs, he has terminated a number of experimental projects, including one AR headset for meetings and a virtual tour product.